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1. Introduction 
Cancer is a leading cause of death world-wide with 7.6 million deaths in 2008 which is 
estimated to rise up to 11 million in 2030. The main cancer types include lung, stomach, liver, 
colorectal and breast cancer (World Health Organization [WHO], 2011). One of three persons 
in developed countries dies of cancer, and the expected survival time of newly diagnosed 
cancer patients (e.g. pancreatic carcinoma) is often less than five years (Kamb, 2005). 
In the last three decades great advances in understanding the molecular bases of cancer 
biology have been made. But up to now cancer therapy is still often empirical, based on 
inhibiting DNA synthesis and cellular division with a high rate of clinical failure. There is 
an unprecedented number of new substances in clinical trials. However, the number of 
highly efficacious drugs approved by the regulatory authorities remains low and there is 
still a desperate medical need for new drugs which are successful for long-term survival 
of patients. Costs for bringing a drug to market are estimated to be over US$ 1 billion 
(Figure 1). This makes the low success rate for oncology products of about 10 percent even 
more disappointing (Hait, 2010). Patients, the pharmaceutical and biotechnology 
community invest enormous efforts to validate new therapeutics only to watch them fail 
in humans due to the lack of suitable model systems. Today commonly used cancer 
models include native human tumor cell lines (e.g. HCT116 colon) or engineered cell lines 
(FLT3.dependent BaF/3 cells). Cancer cell lines provide a certain degree of 
standardization and are easy to handle, but the establishment of cell lines is difficult and 
often they lack key features of the tumor they should model. Improvements for the 
generation of new cancer cell lines are recently made by the introduction of three-
dimensional (3D) culture systems, the selection of tumor initiating cells and the use of 
specialized media. To create a more complex tumor environment cell lines can be grown 
subcutaneously (e.g. PC-3 prostate) or orthotopic (e.g. PC-3 prostate, implanted in 
prostate) in immuno-compromised mice (Kamb, 2005; Caponigro & Sellers, 2011). In 
immuno-compromised mice human cancer cell lines produce tumor-like tissues that show 
a slight resemblance to clinical tumors concerning histological architecture and they fail to 
recapitulate key aspects of human tumorigenicity such as invasion and metastasis. A 
more complex tumor tissue is formed after implantation of whole fragments of human 
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tumors into a mouse. Also mouse tumors can be implanted syngeneically (e.g. B16 
melanoma), induced (radiation induced skin tumors) or genetically engineered (e.g. RIP-
Tag mouse pancreatic islet) (Kamb, 2005). An advantage of mouse models is that 
mechanistic studies can be done in genetically engineered mouse models. As a novel 
strategy in the development of engineered mouse models, chimeric animals are created 
that arise from blastocysts which are injected with engineered stem cells that harbour 
tissue specific inducible oncogenes. These chimeric animals develop tumors in the context 
of normal tissues and could reflect clinical observations accurately such as e.g. distinct 
tumor regression upon anti-EGFR treatment dependent on the mutated oncogene (Zhou 
et al., 2010). Improvements of animal models have been made by using mice with 
humanized haematopoietic and immune systems or by using genetic mouse models that 
include tumor progression and metastasis. But the success of these models remains to be 
determined (Hait, 2010). In 2001 a retrospective study of drug candidates showed only a 
weak correlation between the responses of xenografted tumors to these drugs and the 
clinical outcome (Weinberg, 2006). To counteract this problem preclinical strategies and 
tumor models have to be developed with a robust predictive value for the clinical 




Fig. 1. Time Schedule of the Pharma Drug Development Process. There is an urgent need for 
novel drugs and strategies to fight cancer. However, the development of a single new anti-
cancer agent is very costly (up to 1 billion US$).  Moreover, only very few compounds are 
successful: During long lasting testing of many compounds more and more substances 
become selected as being ineffective until in the end one compound out of 10.000 becomes 
one single approved drug. Reg: Regulation. 
To understand the demands tumor models have to fulfil in the first part of this chapter, we 
are going to give (i) a survey of the historical development of preclinical models, (ii) explain 
different classes of mechanisms of anti-cancer drugs including some examples and problems 
of cytotoxicity, and (iii) summarize the limitations that face preclinical models right now. 
www.intechopen.com
 Three dimensional Tissue Models for Research in Oncology 
 
177 
1.1 History of preclinical tumor models 
The first cancer models were established over 60 years ago and were derived from 
carcinogen-induced mouse tumors, primarily sarcomas and lymphomas (Chabner & 
Roberts, 2005). Observed effects of mustard gas on lymphoid and myeloid cell lineages in 
soldiers were reinvestigated in a transplantable lymphoma model by Gilman and Philips in 
1946 (Gilman & Philips, 1946; as cited in Caponigro & Sellers 2011). This contributed to the 
introduction of in vitro and in vivo models for first successful clinical trials with anti-
neoplastic agents. In the following 30 years these transplantable models were used to 
determine the potential efficacy and toxicity of drugs. In 1957 Heidelberger introduced 5-
fluoruracil, an inhibitor of the pyrimidine biosynthesis pathway, still a key component in 
many cancer treatment regimens today, based on the observation that rat hepatomas show 
an extremly high level of uracil uptake (Heidelberger et al., 1957; as cited in Caponigro & 
Sellers, 2011). Many chemotherapeutic agents used today, such as anti-mitotic vinca 
alkaloids, actinomycin D and platinum salts were discovered or developed during one of 
the first large-scale programmes of the Cancer Chemotherapy National Service Center at the 
US National Cancer Institute. During this program which started in 1955, mouse lymphoma 
models were investigated (Chabner & Roberts, 2005). In the late 1980s, a new concept for the 
application of preclinical models to validate novel therapeutics called NCI60 (National 
Cancer Institute, 60 human tumor cell lines) also included solid tumors in large-scale 
screening platforms. This effort required the use of new technologies, such as performing 
cell culture in microtiter well plates, the development of high-throughput cytotoxicity 
assays, and the establishment of a bioinformatic infrastructure to analyze the large data sets 
being generated (Caponigro & Sellers, 2011). These models provided important insights in 
different mechanisms of cancer cell growth and its inhibition. Recently the role of NCI60 
changed more to a service screen for cancer scientists (Shoemaker, 2006). Even though up to 
now also many tumor cell lines were created from solid tumors, leukemia-lymphoma cell 
lines remain a key tumor model system reflecting the original tumor with high precision 
due to its detailed oncogenomic documentation. But here also some hematopoietic entities 
are underrepresented and resist the establishment of cancer cell lines (Drexler & Macleod, 
2010). New technologies from tissue engineering should also help to generate models with 
immortalized primary cells that maintain differentiation. 
1.2 Mechanisms of anti-cancer drugs 
To optimize the application of preclinical tumor models it is important to understand the 
different ways and mechanisms in which anti-cancer drugs act. These mechanisms can be 
divided into three classes: The first class of agents improves personal therapeutic accuracy 
by targeting genetic dependencies, such as mutations in oncogenes responsible for cancer 
progression. Recent successful examples include imatinib (Gleevec/Glivec; Novartis), which 
targets the activated BCR-ABL gene fusion product in chronic myeloid leukaemia (CML) or 
in gastro-intestinal stromal tumors (GIST) (Kamb, 2005). It is also under investigation for 
application in other cancers as NSCLC. Other biomarkers for patients with NSCLC were 
determined recently and include an activating mutation in the Epidermal-Growth-Factor-
Receptor (EGFR) gene which is recommended to be tested before a treatment with 
therapeutics such as gefitinib or erlotinib is started (Cadranel et al., 2011). Colon cancer 
patients with a mutation in the k-ras gene are excluded from antibody therapy against the 
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EGFR because the targeted pathway is constitutively activated in these patients without any 
influence of the receptor on this activation. Further success in targeted therapy is shown by 
a high clinical response rate of malignant melanoma patients (phase I) to inhibitors of B-RAF 
kinase activity (Bollag et al., 2010). Also the treatment with trastuzumab in metastatic breast 
cancer patients with amplified/overexpressed epidermal growth factor receptor 2 (HER2 or 
ERBB2) showed some success (Vogel et al., 2002). Furthermore mutated downstream 
components of the ras-dependend mitogen-activated protein (MAP) kinase signalling 
pathway, a major regulator of cell survival and proliferation, are attractive targets for 
therapeutic intervention (Fremin & Meloche, 2010). The development of imatinib was driven 
on by mechanistically experimenting with different engineered cancer cell lines and was 
confirmed in xenografted mouse experiments deducing treatment success from the 
inhibition of Abl-protein tyrosine kinase and PDGF receptor activation (Buchdunger et al., 
1996). This indicates that also mechanistically designed experiments using cancer cell lines 
and animal tumor models can lead to clinical success.  
Drugs of the second class of therapeutics target host-tumor interactions, such as hormones 
and secreted factors upon which the tumors depend. They can be developed on the basis of 
hormonal suppression in non-tumor bearing animals. Examples for efficacious therapies are 
aromatase inhibitors for the treatment of oestrogen receptor-positive breast cancer (Baum et 
al., 2002; Caponigro & Sellers, 2011). And recently, abiraterone, an inhibitor of CYP17A, 
revealed some progress in the treatment of castration–resistant prostate cancer by complete 
blocking of androgen synthesis. Prostate cancer depends to 80 percent on androgen the 
biosynthesis of which is catalyzed in the last step by the P450 enzyme CYP17A both in testes 
and in adrenals (Hartmann et al., 2002; Reid et al., 2010). Understanding the molecular 
epidemiology of human tumors should help to promote the development of agents against 
such host factors. 
Agents of the third class of drugs often affect fundamental cellular processes on which cancer 
cells rely more strongly than normal cells. The target population of these therapeutic agents is 
often determined by using the trial-and-error method, a fact that leads to high failure rates 
(Caponigro & Sellers, 2011). Among these drugs of the third class there are common cytotoxic 
chemotherapeuticals such as nucleoside analogues, DNA-modifying chemicals and natural 
products with a narrow therapeutic window that were initially introduced in the 1940s (Kamb, 
2005). As a therapeutic guideline, safe starting doses are estimated from animal toxicology 
studies escalating up to the maximum tolerated dose (MTD), which is defined as the highest 
dose which can be tolerated without any unmanageable side effects. In xenograft animal 
models the efficacy of each drug is estimated from the ratio of tumor volumes in treated 
animals and control animals. The toxicity is estimated from the loss of weight of the animals 
which should be no more than 10 percent during the course of a treatment over two weeks 
(Kamb, 2005). These standard animal experiments correspond only approximately to human 
responses to new substances (Hartung, 2009). Limitations of animal models reside mainly in 
the differences between animals and humans concerning body weight, life span, metabolism 
and drug uptake mechanisms. Results from toxicology studies of different animal species 
show only a concordance in the case of 53-60 percent of all tested chemicals (Schardein et al., 
1985). The toxic effect in humans can be predicted correctly only for 43-63 percent of all the 
tested pharmaceuticals (Olson et al., 2000). In clinical trials made by the pharmaceutical 
industry, 20 percent of the drug candidates showed toxic effects in humans whereas these 
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effects were not detected in animal models (false-negative results). The number of false-
positive results concerning chemicals which are not toxic in humans but could show to be toxic 
in animals is estimated from reproductive toxicity testing in 63 percent of all investigated 
drugs (Hartung, 2009). Data from phase III trials suggest that preclinical models overestimate 
the efficacy of candidate molecules, especially of cytotoxic agents (Caponigro & Sellers, 2011). 
Starting in 1990, over 10.000 compounds per year have been screened in model systems 
derived from eight different solid tumors. Unique patterns of cytotoxicity should help to 
unravel their mechanism of action (Caponigro & Sellers, 2011). Typical cytotoxic 
mechanisms are operated via the inhibition of microtubules and topoisomerases. Novel 
therapeutic mechanisms, such as the inhibition of the proteasome by bortezomib (Velcade; 
Millennium Pharmaceuticals) were recently introduced concerning the treatment of multiple 
myeloma (Adams, 2002). But attention should also be paid to inter-individual variations in 
drug metabolism. For instance, irinotecan is a standard drug in treatment of advanced 
colorectal cancer but 10 percent of the caucasian population show low enzyme activity of an 
important catabolic enzyme and therefore suffer from greater side effects based on the 
toxicity of the drug. Here also individual biomarker tests could reduce the problem of 
superfluous side effects caused by toxicity, because patients with this specific genotype 
should be treated in a different way than people with another genotype (Schilsky, 2010). 
However, with regard to toxicity, it has to be taken into account that cancer is mainly a 
disease of older persons. This augments the problem of drug-toxicity because the 
detoxification becomes more difficult in elderly people.  
1.3 Limitations of preclinical tumor models 
There is a number of typical limitations of preclinical models: Certainly, the number of 
models available does not reflect the number of distinct tumors. Moreover, the molecular 
characterization of models is often inadequate and hence the alignment to human cancers is 
impossible. The observed effects such as tumor growth rate reduction do not necessarily 
correlate with the tumor regression observed in the patient. Moreover, in vitro models 
undergo various selection pressures and biases such as the dependence on oncogenic key 
pathways. The preclinical models do not reflect stromal-tumor interactions. As an exception, 
human cells transplanted in mice exhibit stromal interactions and to a certain content 
angiogenesis. However, these observations still suffer from cross-species differences. 
Furthermore, murine models often actively reject human tumors and hence it is difficult to 
study tumor initiating cells in the murine organism. In contrast, the anti-tumor immunity is 
low to absent in immuno-compromised animals. Finally, the costly and time-consuming in 
vivo testing limits high-throughput screening of substances (Caponigro & Sellers, 2011). 
Tissue engineering could offer new strategies for overcoming the mentioned limitations of 
conventional tumor models and could even improve cost effectiveness and accuracy. 
2. Overview about tissue engineering 
Tissue engineering is an interdisciplinary field that applies the principles of engineering and 
the life sciences to the development of biological substitutes that restore, maintain, or 
improve tissue function (Lavik & Langer, 2004). Potentially, it can create replacement 
structures from biodegradable scaffolds and autologous cells for reconstructive surgery 
(Stock & Vacanti, 2001). According to the U.S. Department of Health and Human Services, 
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meanwhile 110.586 people in the USA are waiting for an organ, and due to the shortage of 
available donor material, an average of 20 potential candidates for organ transplantation die 
each day in the USA. This could be prevented with an artificial alternative for donor tissue 
suitable for transplantation and reconstructive surgery.  
The basic conception of tissue engineering is the cultivation of cells on biocompatible 
scaffolds or matrices, so that they can organize and develop a tissue structure. These 
scaffolds can be composed of synthetic materials like hydroxylapatite (HA) and 
polyurethane (PU) or of biological materials like collagen or decellularized organs. The 
advantage of synthetic materials is the easier availability, but they are not suitable to 
generate all kinds of tissues.  Solid materials like HA are suited very well for the culture of 
e.g. osseous tissue for oral and casualty surgery. Human osteoblasts build 3D structures on 
HA-matrices and are able to calcify without special growth factors [zellwerk.biz]. PU-
matrices have the advantage of biodegradability which means that the matrix disintegrates 
in the body gradually and only the newly grown tissue remains. Moreover, PU scaffolds can 
be formed easily before implantation, so that body parts like e.g. ear cups can be 
reconstructed by using computer tomography (CT) data and can then be implanted after 
having been reseeded with cells. By using collagen/fibronectin gel skin equivalents can be 
cultured which resemble naturally human skin with its two-layered composition very 
closely (Fraunhofer IGB, Stuttgart, Germany). In this model (Figure 2), the dermis is built up 
by using primary dermal fibroblasts deriving from skin biopsies which are embedded into a 
collagen gel. This dermis is used as a basis for the epidermal ceratinocytes which are seeded 
into a fibronectin gel and build up the epidermis. This patent-registered skin model (Patent-
Nr. EP 1 290 145B1) is accredited for the control of biocompatibility of medical products 
(DIN ISO 10993-5). But for dermal reconstructive surgery (e.g. in the case of burns), a graft 
consisting of decellularized bovine skin is used. This kind of matrix consists of collagen 
which is virginally structured and is therefore better suitable for being used as a tissue 
replacement. During the healing procedure, the body’s own fibroblasts produce a collagen 
matrix whereas the transplanted matrix becomes resorbated (Kolokythas et al., 2008).  
 
Fig. 2. Cross section of native skin (A) and skin equivalent (B), hematoxylin and eosin (HE) 
stain. Both samples show a two-layered construction with epidermis (upper part) and 
dermis (bottom). The basal lamina is seen as a thin red line between epidermis and dermis 
in the natural skin (A). 
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Due to the possibility of reseeding the matrices with autologous cells, immune responses are 
reduced or even prevented (Stock & Vacanti, 2001). One example is found among others in 
the area of cardiovascular tissue engineering: The fibrin gel for the production of heart valve 
scaffolds derives from the patient’s blood. Autologous myofibroblasts are injected into this 
gel and after growing the tissue becomes lined with autologous endothelial cells 
(Jockenhoevel et al., 2001). Therefore no heterologous cells are needed. Another advantage 
of the in vitro grown tissue is the ability to expand in the body of the patient. This is very 
important in the case of paediatric surgery because implants which are able to grow do not 
need to be replaced and therefore no additional operations are needed (Jockenhoevel et al., 
2001). For this reason tissue engineering is a very important technology in the field of 
regenerative medicine. Decellularized matrices are also often used for the replacement of the 
viscera like kidney, liver and lung due to their elasticity. Homografts deriving from a 
different organism (e.g. pig) and allografts deriving from an individual of the same species 
(human) are used for generating these matrices.  
In vitro applied bioartificial human tissue models allow the generation of functional 3D cell-
systems mimicking the microenvironment of potential human target tissues which eventually 
reflect the in vivo behaviour of tested cells more precisely than currently applied cell-based test 
systems. Their application in drug research may help to make drug development safer and 
more efficient and reduce research and development expenses. Additionally, they represent 
promising models for individualized oncologic therapy by revealing new insights into 
mechanisms of organogenesis and expression of malignancy (Walles et al., 2007). 
3. Generation of vascularized in vitro tissues 
Our tissue model technology is based on decellularized porcine small bowl segments and 
preserved tubular structures of the capillary network within the collagen matrix which is 
functionally associated with one small vein and artery (biological vascularised scaffold 
[BioVaSc]) (Mertsching et al., 2005). To obtain this biological scaffold BioVaSc (Figure 3) with a 
preserved feeding artery, a draining vein, and a functional capillary network for graft supply, 
we developed a special harvesting procedure in the pigs. Our decellularization procedure left 
behind a dense layer of cross linked collagen and elastin fibers evolved from the stratum 
compactum, the small intestinal submucosa (SIS), the tunica serosa, and the tunica muscularis 
externa with its arterial and venous network. HE staining was used to survey the cellular state 
of each processed matrix (Mertsching et al., 2005). Our decellularization process resulted in 
remaining acellular tubular network of 20 to 200 µm diameter (Fig. 4 A, B) connected to the 
venous and arterial pedicle, respectively, with a basal membrane and elastica interna. Semi 
quantitative DNA detection was applied as molecular marker for scaffold decellularization. Its 
results confirmed our histological findings. Our scaffold thickness was 0.2±0.01 mm. First 
clinical experience shows, that the BioVaSc is well tolerated and supports an extensive tissue 
maturation process following implantation (Mertsching et al., 2009). The functional reseeding 
of the remaining tubular structures of the vascular network within our biological scaffold with 
endothelial cells was the main objective of this study. Microvascular endothelial cells (mECs) 
were identified as the ideal endothelial cell (EC) type in respect to genetic and functional 
stability during isolation, proliferation and seeding in the vascular structures.  To control the 
differentiation of the endothelial cells, we evaluated the endothelial specific markers CD31, 
VE-Cadherin and Flk-1 by immunohistochemistry and western blot analysis. Anyway the 
mECs generate an active antithrombotic surface that facilitates transit of plasma and cellular 
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constituents (Mertsching et al., 2009). For proper function of the endothelium, integrity is 
required, i.e. mainly ensured by endothelial cell-to-cell junctions. A functional vascular 
endothelial lining is of paramount importance to avoid graft thrombosis and failure.  
 
Fig. 3. Standardized method to generate a biological vascularised scaffold (BioVaSc) for the 
engineering of complex vascularised tissues. A part of the porcine jejunum is isolated 
including the feeding artery and vein and the connecting capillary bed. After intensive 
rinsing the cells are removed chemically. The acelluarisation process is finished after a γ-
radiation to sterilize the BioVaSc. 
Three weeks after endovascular seeding and permanent perfusion, the luminal surface of the 
supplying artery and vein is lined with a cellular monolayer staining positive for CD31, which 
mediates adhesion between cells that express CD31. Its expression is limited to endothelial 
cells, platelets, leukocytes, and their precursors and it has been shown to be highly specific and 
sensitive for vascular endothelial cells. Within the scaffold matrix, CD31 positive structures are 
unequally distributed. No positive reaction was detected in acellular controls, excluding non-
specific antibody-reactions with the matrix and remaining porcine endothelial cells in the 
scaffold (Mertsching et al., 2009). Analogical findings were obtained for VE-Cadherin and Flk-
1. VE-Cadherin is an endothelial-specific trans-membrane protein that promotes hemophilic 
cell adhesion mechanically connecting endothelial cells providing the structural base for 
interendothelial mechanical stability. It plays a morphogenic role in vascular development by 
participating in contact inhibition of VEGF signalling and its expression is required for the 
normal organization of the vasculature in the embryo (Carmeliet et al., 1999). Flk-1 is a high-
affinity VEGF-2 receptor and is found on differentiated endothelial progenitor cells. It 
produces a positive endothelial proliferation signal during developmental blood vessel 
formation. Western blot analysis confirmed the immunohistochemical findings. The 
simultaneous expression of three specific endothelial markers on our reseeded biological 
scaffold indicates the successful EC seeding of the vascular structures. Vitality of vascularized 
scaffold was analyzed by 2`-[18F]-fluoro-2`-desoxy-glucose (FDG) positron emission 
tomography (PET) using a dedicated fullring scanner facilitating general graft survey with no 
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need for tissue dissection. As viable cells take up FDG, localized vitality can be in principle 
visualized by PET. To increase the resolution of detected activity distribution, additional thin 
layer scanning was performed. PET images showed 3D activity accumulation within the 
proximity of the reseeded arterial pedicle. Only radioactive background was seen in acellular 
controls. PET imaging allows quantification of the PET signal. Maximum uptake ratios for the 
reseeded biological matrix (perfused with buffer-medium) were 11±0.7 vs. 2±0.9 for the non-
seeded matrix. In addition to this, PET scanning revealed the functional integrity of the 
endothelial vascular lining, thereby supporting our immunohistochemical morphological 
findings. Cellular FDG uptake can be stimulated by insulin exposure and we applied this 
principle as an additional test for functional cellular vitality. Insulin stimulation amplified the 
FDG PET uptake in reseeded matrices by a factor of 4.2±1.1. No increase was detectable in 
acellular controls. These findings amplify our previous findings that the reseeded matrices are 
populated with viable EC (Mertsching et al., 2005).  
The approaches presented here enable the generation of a functional artificial vascular 
network in a porcine scaffold (Fig. 4 A-D). The generated biological vascularized scaffold 
may serve as a universal scaffold for tissue engineering.  
 
Fig. 4. A) The vascularized scaffold (BioVaSc) with blue stained capillary network. B) Seeded 
capillaries of the matrix with fluorescence marked liver endothelial cells. C) A bioartificial 
human tissue model in the specific developed bioreactor enclosed in the closed perfusion stet-
up. D) 3D human vascularised tumor test system with arterial and venous access. 
Pharmaceutical research is hampered by limited predictive value of routinely applied in vitro 
and in vivo drug screening models for clinical efficacy. In drug development, the common 
approach of pharmaceutical industry is to screen small-molecule libraries for function and 
toxicity in biochemical based or ligand binding high-throughput assays (Sundberg, 2000). In 
general enzymes and two-dimensional (2D) cell lines are used in those cell-based assays. The 
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obtained results are of limited biological relevance, since the 2D cell systems do not adequately 
mimic the 3D environment in healthy and tumour tissues (Sundberg, 2000). 
4. Engineered tumor tissues for applied research 
Our BioVaSc can additionally be populated with tumor cells to create ex vivo vascularized 
tumor-like structures. The system offers the option to administer the substances as well as 
nanomaterials in the arterial inflow and to study the influence of the tumor-like tissue 
macroscopically as well as on a cellular and molecular level. Human derived tumor cells are 
co-cultivated with the endothelial cells in such a way that they can form a physiological 
filtration barrier. The medium is conducted over capillaries seeded with endothelial cells to 
the tumor cells. Anti-angiogenic therapy molecules as antibodies are now tested in the 
system. This model offers the possibility to simulate physiological drug application and a 
human 3D test system to established nanomaterials/systems for cancer research/therapy. 
Hackmann and Redelmeier have found out in 2006 that 92 percent of the new drugs fail in 
clinical studies although the animal experiments were successful (Hackam & Redelmeier, 2006; 
as cited in Schanz et al., 2010). And it is not least for ethical reasons that suitable alternatives 
should be found for animal experiments. Already established test tissues at Fraunhofer IGB 
are the intestine, liver, trachea and fascia models. The cultivation of the cells must take place in 
special bioreactors in which nutrients can be fed and metabolism products can be removed 
and which reflect the conditions in the human body in this way (Fig. 4 C, D). These test 
systems will be transferred into tumor test systems. The heterologous cellular micro-
environment of a tumor can be copied by co-culture of tumor cells with stroma cells like 
fibroblasts. This is important, because the cancerogenesis is influenced by interactions of 
stroma, epithelium and components of the extracellular matrix (Micke & Ostman, 2004). The 
main application will be the testing of patient-specific therapies like drugs, chemotherapy, and 
immunotherapy. In this manner one can test new therapies and drugs outside the patient, but 
within human (perhaps autologous) tissue before they find use in the cancer therapy.  
Why do we need tumor test systems? Up to now there are no suitable human in vitro models 
of cancer available as described in “the biology of cancer” (Weinberg, 2006). But why do we 
need as many “nature identical” tumor models generated from human cells? The first reason is 
that new therapies and new drugs are needed to fight cancer by inhibiting tumor growth, 
angiogenesis as well as tumor metastasis. To test the effects of many different substances on 
these processes of tumor development, a time-saving and standardized method is used. The 
widely used animal xenograft animal models show some advantages for being used as a test 
system e.g. the interaction between tumor and the whole living organism including blood 
circulation. The immune system can be studied as well as psychophysiological consequences 
of medication which can be analyzed during behavioural studies of the animals. But on the 
other hand there are many pros for the in vitro tumor models: the generation of such in vitro 
tumors is not as time-consuming as the breeding and fostering of animals used for xenograft 
transplantation, a circumstance which is very interesting for high-throughput screening of 
drugs and diverse therapeutical methods from a wide pool of possible cancer treatments. 
Moreover, in vitro tumor models do not contain any unrelated cells from other species which 
interact with the human cell population and can bias the results. And, last but not least, the in 
vitro tumor models can be standardized better than any living organism can be. Additionally, 
synthetic human tumors cultured in 3D do not suffer psychologically from treatment and for 
this reason can be supported from an ethical point of view for first drug screening.   
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Another important field is the so-called “personalized medicine”, a very individual tumor 
treatment for each patient. As not only each patient but also each tumor can be seen as an 
individual, it is very important to individualize treatment, too. A big aim for the future is 
the cultivation of primary cells deriving from the special tumor of the individual patient. 
These primary tumor cells can be used to build up artificial tumors in vitro which can also be 
medicated in vitro and which can be used for analyzing the characteristic features of this 
special disease e.g. the genetic background of the tumor cells, their interaction with 
surrounding tissue cells and their responsiveness to various treatments. All these studies 
can be done in parallel by using an array of these in vitro tumor models. By using these 
models it could be possible to circumvent side effects of inefficient treatments and it could 
be possible to adjust tumor treatment within a short period of time because of the parallel 
investigation possibilities. For the investigation of tumor-stroma interactions these in vitro 
tumor models are also very useful. Activated cancer-associated fibroblasts e.g. are involved 
in tumor progression and are a possible target for anti-cancer therapies (Kalluri & Zeisberg, 
2006). Dermal fibroblasts can be isolated quite easily from skin biopsies and can be 
employed to mimic these interactions between tumor cells and connective tissue in the 
human body. Also the interaction between endothelial cells and the tumor cells can be 
investigated in an artificial tumor especially when it is grown and cultured in a bioreactor 
with an artificial “blood stream”. In this dynamic system it is possible to study the 
angiogenesis of the tumor and to identify signals between tumor cells and endothelial cells 
as well as to test the ability of drugs to inhibit these interactions. Also signal pathways 
involved in tumor development can be analyzed in these artificial tumors generated by co-
cultivation of tumor cells and stroma cells as well as extracellular matrix components 
involved in carcinogenesis (Micke & Ostman, 2004).  
5. Examples for 3D tissue models for research in oncology 
An in vitro model of malignant melanoma was created by using of the 3D skin model 
developed by the Fraunhofer company (EP 01953961.8-2405). Different types of melanoma 
cells can be used to create skin tumors on or in this dermal equivalent. 
Malignant melanomas often differ in invasiveness as well as tumor expansion. There must 
be various subtypes of melanomas and for this reason it is important to investigate the 
features of this special tumor which a single patient suffers from. To characterize the 
pathogenical background of different tumors and to test various medical therapies in vitro, 
this 3D skin model developed by the Fraunhofer IGB (EP 01953961.8-2405) can be used. 
Additionally, it can be useful in testing pharmaceutical penetration and resorption of 
different drugs. The test tissue was generated as described in [Walles et al., 2007]: Human 
primary fibroblasts derived from human foreskin (1 x 104 cells/cm2) were seeded in a rodent 
collagen-I gel (isolated from rat tail) resulting in a dermal-like cell-matrix construct. Human 
ceratinocytes (1 x 105 cells/cm2) were seeded on the surface of the cell-matrix construct and 
incubated for 5 days in cell culture medium (submerged cell culture). The “epidermal” 
ceratinocyte layer of the tissue surface was exposed to the air for another 12-14 days to 
induce ceratinization (air-lift culture). The resulting tissue was composed of a stable 
connective tissue rich of cells (= dermis) with a ceratinizing surface. 
Now different human melanoma cell lines were inoculated into the dermal layer and 
showed their characteristic growth behavior in these in vitro models (Figure 5).  
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Fig. 5. Bioartificial human in vitro skin model for malignant melanoma spread. A) Superficial 
spreading melanoma (SSM) diffusely infiltrating the skin equivalent. B) Nodular melanoma 
(NM) forming tumor nests. C) Lentigo maligna melanoma (LMM) spreading superficially 
without invasion of the skin equivalent. (Adapted from Walles et al., 2007) 
Additionally, an interaction between tumor tissue and endothelial cells could be shown 
when they were co-cultivated in this model (Walles et al., 2007). For this reason, also 
endothelial cell differentiation as well as angiogenesis can be analyzed with this model as 
well as the development of medical devices, e.g. a laser assisted diagnostic device for 
melanoma can be developed using such an in vitro model (Mertsching et al., 2008).  
Because lung cancer is the most common cancer in terms of both incidence and mortality 
(Jemal et al., 2011) it is very important to develop new and better therapeutic approaches. 
An in vitro model of lung adenocarcinoma was created by using the BioVaSc reseeded with 
A549 tumor cells as well as primary dermal fibroblasts in co-culture. A549 cells are a lung 
cancer cell line derived from adenocarcinomic human alveolar basal epithelial cells. Results 
showed that the primary fibroblasts influenced the growth of the tumor cells concerning 
growth behavior and morphology and formed nodular structures in some areas (Wasik, 
2011). Immortalized cell lines derived from tumor cells are a good basic material to build up 
standardized in vitro tumors because primary cells derived from tumor biopsies are not as 
uniform as these cell clones. There are different matrices which can be used as a substrate 
for the 3D cell culture e.g. inserts of polycarbonate.  
Another important field of cancer research is colon cancer because it is the second most 
common cancer disease in Germany and kills about 600.000 people annually worldwide 
[globocan.iarc.fr]. An in vitro model for colon adenocarcinoma which was also created by 
using the BioVaSc reseeded with cells of different cancer cell lines derived from colon 
adenocarcinomas (Caco-2 and SW480) as well as dermal primary fibroblasts and mECs 
which were co-cultured with the cancer cells. In this model, the SW480 cells show nodular 
growth in co-culture with primary fibroblasts and exhibit a more malignant morphology 
than Caco-2 cells. To test the influence of substances on tumor growth and invasiveness, in 
vitro models built up from human colon carcinoma cells are in very dire need because 
animal xenograft models have some drawbacks especially concerning such studies of the 
gut: mice or rats have a very different diet compared to man and in consequence of this their 
gut not only a “miniature edition” but it is different in some ways compared to the human 
one e.g. the gut flora is very different or food does not stay as long in the gut as in humans. 
First models are built up by using various colon carcinoma cell lines e.g. the well-established 
cell lines Caco-2 and SW480. Budding results could be seen concerning the more aggressive 
SW480 cells which invade the matrix in monoculture and showed nodular structures in co-
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culture with fibroblasts (own data, unpublished). But more read outs for tumor features of 
these in vitro “tumors” are needed e.g. proliferation quantification as well as verification of 
an upcoming epithelial mesenchymal transition (EMT).  
6. Conclusion 
Conventional preclinical tumor models were proved to be successful in some limited 
settings when the cell models, the human xenografts or the mouse model include mutations, 
amplifications or translocations of the original malignancy that was to be treated in the 
clinic. Also important aspects such as pharmacokinetic behaviour, tissue distribution and 
percentage of free compounds in plasma can be determined in conventional animal tumor 
models. However, there is a tendency to overestimate the real clinical impact of any 
compound measured by reduction of the tumor mass in xenograft models. Nowadays 
genetically engineered mouse models are ever more sophisticated but still habour additional 
unknown changes which challenge the translation to the patient (Kamb, 2005). Other 
drawbacks of conventional models remain, such as the insufficient number of experiments 
for proper statistics, the time-consuming generation of animal models and the low number 
of cell lines that do not represent the tumors’ heterogeneity (Kamb, 2005).  
Cancer is foremost a genetic disease, making the analysis of correlation between compound 
activity and molecular changes important (Caponigro & Sellers, 2011). Averagely about 80 
genes are affected in different common tumor types as breast and colon cancer (Todaro et 
al., 2010) which makes clear that 60 cancer cell lines can not accurately reflect the diversity of 
over 100 histologically distinct tumor types. Progress in drug development requires the 
identification of essential and compensating functions that are specific to cancer cells and 
their translation in a proper tumor model.  
At present many projects try to identify gene signatures in screens of large sets of cell lines 
that predict sensitivity and resistance to specific targeted drugs. For example, the Novartis 
Institutes for BioMedical Research in collaboration with other investigators assembled in the 
“Cell Line Encyclopedia Project“ expression profiles, copy-number alterations and dose-
response data of over 1000 cell lines (Caponigro & Sellers, 2011). Other promising 
approaches for targeted drug development are current genome-profiling projects such as the 
National Cancer Institute’s “Cancer Genome Atlas” and the Sanger’s Institute’s “Cancer 
Genome Project” (Schilsky, 2010). However, while relating targeted anti-cancer drug 
efficacy and toxicity it is important to consider physiology. In organisms from E. coli to 
mouse three quarters of the individual genes are non-essential or only essential in a 
particular genetic or epigenetic background. This explains why tumors often not depend on 
the target for viability (Kamb, 2005). 
Another approach for successful cancer therapy is the testing of different drug combinations 
in sufficiently large sets of in vitro models where many compounds can be tested in one cell 
line or one combination in many different cell lines. In some cases combination therapy 
could also overcome acquired drug resistance. 
In future it would be a desirable goal to create in vitro tumor models by using primary cells 
derived from the patient’s tumor biopsies to get to test various therapeutic approaches on 
autologous test systems in vitro before application. Therefore this personalized medicine 
would be the best to avoid side effects of ineffective treatments and to save time and 
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therefore lives because many therapeutic methods can be tested in parallel in vitro on their 
effectiveness in fighting this special tumor before being given to the patient. For successful 
personalized medicine further biomarkers such as k-ras in anti-EGFR colon cancer therapy 
have to be identified and diagnostic tests have to be co-developed with new drugs (Hait, 
2010). To accelerate the development and approval of targeted cancer therapies, clinical 
investigators, scientists, drug developers and regulatory experts joined by the Brookings 
Institution and have recently proposed a novel strategy for drug and biomarker co-
development called “targeted approval” (Schilsky, 2010). Tumor models with higher 
efficiency and accuracy should be generated with cell lines harbouring certain mutations 
that are targeted by drugs the impact of which is predicted by bioinformatic analysis of 
genomic and epigenomic screens. 
It has been proven that personalized medicine could also improve cost efficiency in 
prescription practice: Stratification of patient population that should be treated with certain 
agents such as the use of anti-EGFR drugs only in k-ras wild-type colorectal cancer patients. 
This could save the US health care system about US$ 700 million annually (Schilsky, 2010). 
Not only is the development of novel drugs expensive but also the drugs themselves and the 
following treatment protocols. The National Institute of Health of the United States 
estimated the overall cost of cancer care in 2007 to US$ 219.2 billion. Cost-utility studies for 
cancer started initially in the 1990s and extended to 14 percent in 2007, which gives hope to 
improve cost-effectiveness in cancer in future (Greenberg et al., 2010). 
In general new approaches have to be considered to bring more successful anti-cancer 
agents to market. If a strong genetic and epidemiological indication exists for any drug more 
caution should be applied before excluding these rashly from the clinic (Kamb, 2005). 
Toxicity models should balance sensitivity (false-negative rate) with selectivity (false-
positive rate) (Kamb, 2005). Treatment-related deaths in Phase I oncology have fallen down 
to a fraction of a percentage point (Roberts et al., 2004) and therefore regulatory agencies 
should reconsider the criteria for advancement into the clinic to improve the throughput of 
drug testing in humans. However, there is a need for global regulation to judge which 
criteria form the basis of approval of drugs which are active but have no significant side 
effects (Hait, 2010). 
Last but not least there is hope to improve clinical applications also due to impressive and 
well-coordinated ventures occurring worldwide that could go along with the generation of 
more complex and accurate preclinical 3D tumor models in the field of tissue engineering to 
fight cancer. 
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